Patents Assigned to Semafore Pharmaceuticals, Inc.
-
Patent number: 7662977Abstract: The invention provides novel prodrugs of inhibitors of PI-3 kinase. The novel compounds are LY294002 and analogs thereof comprising a reversibly quaternized amine.Type: GrantFiled: December 21, 2007Date of Patent: February 16, 2010Assignee: Semafore Pharmaceuticals, Inc.Inventors: Joseph R. Garlich, Donald L. Durden, Mary Patterson, Jingdong Su, Robert G. Suhr
-
Publication number: 20090011975Abstract: The invention provides a method of inhibiting cell death in a mammal. The method comprises administering to a mammal an effective amount of a composition comprising a cell protection factor covalently linked to a bone targeting agent via a linkage that is cleaved under physiological conditions, whereby the cell protection factor is released from the bone targeting agent in vivo to inhibit cell death. The invention further provides a compound comprising a cell protection factor covalently attached to a bone targeting agent via a linker that is cleaved under physiological conditions.Type: ApplicationFiled: July 31, 2008Publication date: January 8, 2009Applicant: Semafore Pharmaceuticals Inc.Inventors: Joseph R. Garlich, Donald L. Durden, Tim C. Smith
-
Publication number: 20080292714Abstract: This invention provides a method of modifying a cellular response in a mammal. The method comprises administering to the mammal an effective amount of biodegradable nanoparticles, each of said nanoparticles comprising an active agent, a biodegradable polymer, and a bone targeting agent administering to a mammal an effective amount of a composition comprising a compound absorbed in a biodegradable nanoparticle which is attached to a bone targeting agent. The invention also provides a method for modifying a cellular response in a mammalian cell comprising contacting the mammalian cell with biodegradable nanoparticles. The invention further provides a method of delivering an exogenous substance to a mammal. The method comprises administering to the mammal a composition comprising the exogenous substance absorbed into a biodegradable nanoparticle, wherein the biodegradable nanoparticle is covalently attached to a bone targeting agent.Type: ApplicationFiled: July 29, 2008Publication date: November 27, 2008Applicant: Semafore Pharmaceuticals Inc.Inventors: Joseph R. Garlich, Donald L. Durden, Lisa Brannon-Peppas, Tim C. Smith
-
Patent number: 7396828Abstract: The invention provides prodrugs of inhibitors of PI-3 kinase. The compounds are LY294002 and analogs thereof comprising a reversibly quaternized amine.Type: GrantFiled: April 20, 2005Date of Patent: July 8, 2008Assignee: Semafore Pharmaceuticals, Inc.Inventors: Joseph R. Garlich, Donald L. Durden, Mary Patterson, Jingdong Su, Robert G. Suhr
-
Publication number: 20070203098Abstract: The therapeutic use of inhibitors of PTEN activity in the treatment of PTEN-mediated diseases, conditions, and injuries is disclosed.Type: ApplicationFiled: April 6, 2005Publication date: August 30, 2007Applicant: Semafore Pharmaceuticals, Inc.Inventors: Joseph Garlich, Donald Durden, Taxiarchis Georgiadis, Jingdong Su, Xiaodong Peng, Tim Smith
-
Patent number: 6949537Abstract: The invention provides novel prodrugs of inhibitors of PI-3 kinase. The novel compounds are LY294002 and analogs thereof comprising a reversibly quaternized amine.Type: GrantFiled: April 5, 2004Date of Patent: September 27, 2005Assignee: Semafore Pharmaceuticals, Inc.Inventors: Joseph R. Garlich, Donald L. Durden, Mary Patterson, Jingdong Su, Robert G. Suhr
-
Publication number: 20040198783Abstract: The invention provides a method of inhibiting cell death in a mammal. The method comprises administering to a mammal an effective amount of a composition comprising a cell protection factor covalently linked to a bone targeting agent via a linkage that is cleaved under physiological conditions, whereby the cell protection factor is released from the bone targeting agent in vivo to inhibit cell death. The invention further provides a compound comprising a cell protection factor covalently attached to a bone targeting agent via a linker that is cleaved under physiological conditions.Type: ApplicationFiled: April 2, 2004Publication date: October 7, 2004Applicant: Semafore Pharmaceuticals Inc.Inventors: Joseph R. Garlich, Donald L. Durden, Tim C. Smith